A Multicentric Experience on Living Donor Liver Transplantation in Coronavirus Disease 2019 Hotspots in India

Varghese, Joy; Malleeswaran, Selvakumar; Patcha, Rajanikanth; Appusamy, Ellango; Karnan, Perumal; Kapoor, Dharmesh; Venugopal, K.; Kedarisetty, Chandhan Kumar; Rao, Prashantha; Yalakanti, Raghavendra Babu; Mohanka, Ravi; Shrimal, Anurag; Nikam, Vinayak; Kumar, Karan; Shenvi, Sunil D.; Venugopal, Bhaskaran Pillai; Heaton, Nigel

doi:10.1002/lt.25957

Cited by 12 publications

(10 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…‐A multicentre study from India (LDLT = 31) reported on the perioperative safety and good outcomes in carefully timed LDLT (1 COVID‐19 infected), even in COVID‐19 hotspots 132 …”

Section: Liver Manifestations and Disease‐specific Management For Pat...mentioning

confidence: 99%

COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later

Ekpanyapong

Bunchorntavakul

Reddy

2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has affected people from different parts of the World and has been a major cause for significant morbidity and mortality to date. Coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, can present with various clinical features and while pulmonary manifestation is the most common, hepatic abnormalities can be encountered in up to 50% of infected individuals. 1,2 The spectrum is variable and can range from asymptomatic abnormalities in hepatic biochemical tests to severe liver injury with some reports of acute-on-chronic liver failure in patients with underlying cirrhosis. [3][4][5] Hepatic dysfunction has been associated with poor outcome and which has been noted to be more frequent in critically ill

show abstract

“…‐A multicentre study from India (LDLT = 31) reported on the perioperative safety and good outcomes in carefully timed LDLT (1 COVID‐19 infected), even in COVID‐19 hotspots 132 …”

Section: Liver Manifestations and Disease‐specific Management For Pat...mentioning

confidence: 99%

COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later

Ekpanyapong

Bunchorntavakul

Reddy

2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…After excluding age, diabetes and chronic kidney disease significantly associated with mortality Polak 4 244 36 (14.7%) died, internet based survey Webb 34 39 Data from registry, 9 (23%) died, 4 of death happened in patients transplanted < 2 years back, 4 of died had diabetes and hypertension, 3 were obese Rabiee 35 112 25 (22.3%) died, LT recipients had lower acute liver injury when compared to age and sex matched CLD, reduction of immunosuppression was not associated with liver injury/mortality. ALI significantly associated with mortality Lee 36 38 7 died (18% overall, 29% of hospitalized) Dumortier 37 104 20 died, age independently associated with mortality Becchetti 38 57 7 died (12%), 5 of 7 mortalities happened in cases with history of cancers Colmenero 39 111 31.5% had severe disease, 20 (18%) mortality Webb 40 151 28 (19%) died, when compared to matched non-transplant population, mortality was not high in transplant recipients Dhampalwar 41 12 1 died Case reports or small series 32 , 42 , 43 , 44 , 45 , 46 27 9 died Total 1138 211 died (18.5%) …”

Section: Introductionmentioning

confidence: 99%

Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation

Choudhary

Dhampalwar

Saraf

et al. 2021

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is associated with a significant morbidity and mortality in patients with cirrhosis. There is a significantly higher morbidity and mortality due to COVID-19 in patients with decompensated cirrhosis as compared to compensated cirrhosis, and in patients with cirrhosis as compared to non-cirrhotic chronic liver disease. The fear of COVID-19 before or after liver transplantation has lead to a significant reduction in liver transplantation numbers, and patients with decompensated cirrhosis remain at risk of wait list mortality. The studies in liver transplantation recipients show that risk of mortality due to COVID-19 is generally driven by higher age and comorbidities. The current review discusses available literature regarding outcomes of COVID-19 in patients with cirrhosis and outcomes in liver transplant recipients.

show abstract

“…In a multicenter Indian study involving 31 living donor LT patients (21 adults and 10 pediatric patients) from April to July 2020, one patient developed SARS-CoV-2 infection 46 days after surgery and was recovering at the time of publication [45]. In this patient, mycophenolate mofetil was stopped, and the doses of tacrolimus and steroids were modified.…”

Section: Solid-organ Transplantation (Sot)mentioning

confidence: 99%

“…None of the donors or transplant team members developed SARS-CoV-2 infection during the study period. The authors emphasized the importance of maintaining strict protocol in preventing the development of COVID-19 in the recipients, donors, or transplant team members [45].…”

Section: Solid-organ Transplantation (Sot)mentioning

confidence: 99%

Impact of COVID-19 on the outcomes of gastrointestinal surgery

Gupta

Ammar

2021

Clin J Gastroenterol

View full text Add to dashboard Cite

COVID-19 pandemic has brought a paradigm shift in the treatment of various surgical gastrointestinal disorders. Given the increasing number of patients requiring hospitalization and intensive care for SARS-CoV-2 infections, various surgical departments worldwide were forced to stop or postpone elective surgeries to save the health resources for COVID-19 patients. Since the declaration of the COVID-19 pandemic by the World Health Organization on 12th March 2020, the recommendations from the surgical societies kept evolving to help the surgeons in making informed decisions regarding patient care. Moreover, various socio-economic and epidemiological factors have come into play while deciding the optimal approach towards patients requiring gastrointestinal surgery. Surgeries for many abdominal diseases such as acute appendicitis and acute calculous cholecystitis were postponed. Elective surgeries were triaged based on the urgency of performing the surgical procedure, the hospital burden of COVID-19 patients, and the availability of healthcare resources. Various measures were adopted such as preoperative screening for SARS-CoV-2 infection, use of personal protective equipment, and the COVID-19-free surgical pathway to prevent perioperative SARS-CoV-2 transmission. In this article, we have reviewed the recent studies reporting the outcomes of various gastrointestinal surgeries in the COVID-19 pandemic era and the recommendations from various surgical societies on the safety precautions to be followed during gastrointestinal surgery.

show abstract

A Multicentric Experience on Living Donor Liver Transplantation in Coronavirus Disease 2019 Hotspots in India

Cited by 12 publications

References 4 publications

COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later

COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later

Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation

Impact of COVID-19 on the outcomes of gastrointestinal surgery

Contact Info

Product

Resources

About